close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

119.05 -0.73 (-0.61%)
Streaming Delayed Price Updated: 3:57 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Abivax Announces Results of its June 6, 2025 Annual General Meeting
From Abivax
Via GlobeNewswire
News headline image
Abivax Presents First Quarter 2025 Financial Results
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
From Abivax
Via GlobeNewswire
News headline image
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
From Abivax
Via GlobeNewswire
News headline image
Earnings Scheduled For March 24, 2025 ↗
 
Via Benzinga
News headline image
Abivax Announces Full Year 2024 Financial Results
From Abivax
Via GlobeNewswire
News headline image
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
From Abivax
Via GlobeNewswire
News headline image
Abivax Publishes 2025 Financial Calendar
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
From Abivax
Via GlobeNewswire
News headline image
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces a Change to the Composition of its Board of Directors
From Abivax
Via GlobeNewswire
News headline image
This Veeva Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
From Abivax
Via GlobeNewswire
News headline image
Abivax presents third quarter 2024 key financial information
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
From Abivax
Via GlobeNewswire
News headline image
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
From Abivax
Via GlobeNewswire
News headline image
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
From Abivax
Via GlobeNewswire
News headline image
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
From Abivax
Via GlobeNewswire
News headline image
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
From Abivax
Via GlobeNewswire
News headline image
Abivax presents first-half 2024 financial results
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
From Abivax
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today